Within the next five years, large pharmaceutical companies are projected to outsource more than 50 percent of their commercial activities, according to a 2025 report by professional services network EY. Fueling this trend are growing regulatory complexities within the pharmaceutical market and the need for commercialization expertise to help launch new drugs in the face of increased demands for specialized medications.
PE snaps up pharmaceutical commercialization assets: 5 deals
DFW, Great Point Partners, SK Capital and Water Street Healthcare Partners are among the PE firms investing in pharma commercialization services.
